Balyasny Asset Management is primarily a multi-strategy asset management firm aiming to generate consistent, uncorrelated returns across various market environments through diverse strategies including equities, fixed income, commodities, and systematic approaches. The firm has also launched its first dedicated venture capital fund, Atlas Growth LP, which focuses on growth-stage enterprise technology startups in sectors such as AI, data infrastructure, healthtech, and cybersecurity, with a strategy to maintain a concentrated portfolio.
33% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Their most common stage is series-c (50% of deals). Average disclosed round size is $216.3M (across 6 rounds with reported amounts).
Portfolio
6
Fund Size
—
Top Stage
Series C
Last 12 Mo
3
Team
Mayank Chamadia
Partner & Portfolio Manager, Head of New York Fixed Income & Macro
Sebastiaan De Boe
Partner & Portfolio Manager, Head of EMEA Equities
Dan Deighton
Global Head of Commodities
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
| SSolve Therapeutics, Inc. | Series D | $120M | Nov 2025 |
 Forterra | Series C | $238M | May 2025 |
 RapidSOS | Growth | $150M | Mar 2024 |
 Avant | Growth | $325M | Sep 2015 |
 Nature's Fynd | Series C | $350M | — |
Top Co-Investors
Last updated: 5 March 2026